Nocturne Acquisition Corporation (MBTC)
| Market Cap | 61.00M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.32M |
| Shares Out | 5.19M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 202 |
| Open | 11.75 |
| Previous Close | 11.44 |
| Day's Range | 11.75 - 11.75 |
| 52-Week Range | 10.32 - 11.88 |
| Beta | 0.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About MBTC
Nocturne Acquisition Corporation does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Wilmington, Delaware. [Read more]
Financial Performance
Financial StatementsNews
Chardan Engaged to Facilitate Nocturne Acquisition Corporation's Business Combination with Cognos Therapeutics, Inc., Paving the Way for NASDAQ Listing
WILMINGTON, Del. and INGLEWOOD, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Nocturne Acquisition Corporation (NASDAQ:MBTC, MBTCU, MBTCR) ("Nocturne") and Cognos Therapeutics, Inc. (“Cognos”) today anno...
Nocturne Acquisition Corporation Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Cognos
Transaction Expected to Accelerate the Research and Advancement of Cognos' Proprietary and Innovative Implantable Drug Delivery Pump to Improve Outcomes for Treatment of Brain Cancers and Other Neurol...
Nocturne Acquisition Corporation Announces Receipt of a Second Notification from Nasdaq
WILMINGTON, DE / ACCESSWIRE / May 30, 2023 / Nocturne Acquisition Corporation (NASDAQ:MBTC, MBTCU, MBTCR) (the "Company", "MBTC"), today announced that it has received a second notification (the "Seco...
Cognos Therapeutics, Inc. to Become Publicly Listed on Nasdaq via Business Combination with Nocturne Acquisition Corporation
Cognos Therapeutics is a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenera...
Nocturne Acquisition Corp. Confirms Funding to Extend Period to Consummate Initial Business Combination
WILMINGTON, DE / ACCESSWIRE / July 5, 2022 / Nocturne Acquisition Corp. (NASDAQ:MBTCU) (the "Company"), announced today that an aggregate of $1,150,000 (the "Extension Payment") has been deposited int...
Nocturne Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
LA JOLLA, CA / ACCESSWIRE / June 4, 2021 / Nocturne Acquisition Corporation (NASDAQ:MBTCU) (the "Company") today announced that it has received a notice ("Notice") from the Listing Qualifications Depa...
Nocturne Acquisition Corporation Announces the Separate Trading of its Ordinary Shares and Rights, Commencing May 3, 2021
LA JOLLA, CA / ACCESSWIRE / April 29, 2021 / Nocturne Acquisition Corporation (NASDAQ:MBTCU) (the "Company" or "MBTC") announced that, commencing May 3, 2021, holders of the units sold in the Company'...
Nocturne Acquisition Corporation Announces Closing of Fully-Exercised Over-Allotment Option in Connection with Its Initial Public Offering
LA JOLLA, CA / ACCESSWIRE / April 14, 2021 / Nocturne Acquisition Corporation (NASDAQ:MBTCU), the "Company") announced today that the underwriters in its initial public offering, pursuant to the terms...
Nocturne Acquisition Corporation Announces Closing of $100 Million Initial Public Offering
LA JOLLA, CA / ACCESSWIRE / April 5 , 2021 / Nocturne Acquisition Corporation (the "Company"), a special purpose acquisition company, today announced the closing of its initial public offering of 10,0...
Nocturne Acquisition Corporation Announces Pricing of $100 Million Initial Public Offering
LA JOLLA, CA / ACCESSWIRE / March 31 , 2021 / Nocturne Acquisition Corporation (the "Company"), a special purpose acquisition company, today announced the pricing of its initial public offering of 10,...